2024
Cognitive Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder With Obesity: A Randomized Controlled Trial.
Grilo C, Ivezaj V, Tek C, Yurkow S, Wiedemann A, Gueorguieva R. Cognitive Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder With Obesity: A Randomized Controlled Trial. American Journal Of Psychiatry 2024 PMID: 39659158, DOI: 10.1176/appi.ajp.20230982.Peer-Reviewed Original ResearchCognitive-behavioral therapyBinge-eating disorderEffectiveness of cognitive-behavioral therapyBinge-eating remission ratesEating-disorder psychopathologyCognitive behavioral therapyEvidence-based treatmentsRemission ratePercent weight lossHigher remission ratesBinge-eating frequencyBehavioral therapyPosttreatment assessmentLisdexamfetamineRandomized controlled trialsHeightened ratesCostly public health problemIntention-to-treat ratesFunctional impairmentWeight lossControlled trialsDisordersPosttreatmentIndividualized treatmentMixed modelsLisdexamfetamine maintenance treatment for binge-eating disorder following successful treatments: randomized double-blind placebo-controlled trial
Grilo C, Ivezaj V, Yurkow S, Tek C, Wiedemann A, Gueorguieva R. Lisdexamfetamine maintenance treatment for binge-eating disorder following successful treatments: randomized double-blind placebo-controlled trial. Psychological Medicine 2024, 54: 3334-3344. PMID: 39258475, PMCID: PMC11496227, DOI: 10.1017/s003329172400148x.Peer-Reviewed Original ResearchEating-disorder psychopathologyBinge-eating disorderMaintenance treatmentAcute treatmentBinge-eating remission ratesCognitive-behavioral therapyEfficacy of lisdexamfetamineSignificant weight gainDouble-blind placebo-controlled trialAcute respondersLisdexamfetamine treatmentPsychopathological outcomesPosttreatment assessmentLisdexamfetaminePlacebo-controlled trialRandomized double-blind placebo-controlled trialSingle-site trialAssociated with significant weight lossPsychopathologyBinge-eatingRemission rateWeight lossPlaceboRelapse rateControl research
2017
Alpha‐lipoic acid (ALA) as a supplementation for weight loss: results from a meta‐analysis of randomized controlled trials
Kucukgoncu S, Zhou E, Lucas K, Tek C. Alpha‐lipoic acid (ALA) as a supplementation for weight loss: results from a meta‐analysis of randomized controlled trials. Obesity Reviews 2017, 18: 594-601. PMID: 28295905, PMCID: PMC5523816, DOI: 10.1111/obr.12528.Peer-Reviewed Original ResearchConceptsAlpha-lipoic acidBody mass indexAlpha-lipoic acid treatmentPlacebo groupWeight lossEffect of ALASignificant short-term weight lossShort-term weight lossModest weight lossPlacebo treatment groupsPlacebo-controlled studyWeight changeAnti-obesity propertiesSystematic literature searchMeta-regression analysisMass indexSignificant morbidityALA doseBMI changeLong-term benefitsWeight managementBMI differencesTreatment groupsMortality rateStudy duration
2007
A pilot study of a weight management program with food provision in schizophrenia
Jean-Baptiste M, Tek C, Liskov E, Chakunta UR, Nicholls S, Hassan AQ, Brownell KD, Wexler BE. A pilot study of a weight management program with food provision in schizophrenia. Schizophrenia Research 2007, 96: 198-205. PMID: 17628437, DOI: 10.1016/j.schres.2007.05.022.Peer-Reviewed Original ResearchConceptsWeight lossSignificant medical risksMeaningful weight lossWeight loss programWeight management programSevere mental illnessSerious medical problemLifestyle modificationComorbid obesityLoss programPilot trialGeneral populationMetabolic indicesCognitive impairmentMental illnessMedical riskMedical problemsWeight gainObesityPilot studySpecific populationsSchizophreniaBehavioral programHealthy foodsReplacement program